Literature DB >> 20066657

Gene transfer into rat brain using adenoviral vectors.

Mariana Puntel1, Kurt M Kroeger, Nicholas S R Sanderson, Clare E Thomas, Maria G Castro, Pedro R Lowenstein.   

Abstract

Viral vector-mediated gene delivery is an attractive procedure for introducing genes into the brain, both for purposes of basic neuroscience research and to develop gene therapy for neurological diseases. Replication-defective adenoviruses possess many features which make them ideal vectors for this purpose-efficiently transducing terminally differentiated cells such as neurons and glial cells, resulting in high levels of transgene expression in vivo. Also, in the absence of anti-adenovirus immunity, these vectors can sustain very long-term transgene expression within the brain parenchyma. This unit provides protocols for the stereotactic injection of adenoviral vectors into the brain, followed by protocols to detect transgene expression or infiltrates of immune cells by immunocytochemistry or immunofluorescence. ELISPOT and neutralizing antibody assay methodologies are provided to quantitate the levels of cellular and humoral immune responses against adenoviruses. Quantitation of adenoviral vector genomes within the rat brain using qPCR is also described.

Entities:  

Mesh:

Year:  2010        PMID: 20066657      PMCID: PMC2883311          DOI: 10.1002/0471142301.ns0424s50

Source DB:  PubMed          Journal:  Curr Protoc Neurosci        ISSN: 1934-8576


  71 in total

1.  Long-term transgene expression can be mediated in the brain by adenoviral vectors when powerful neuron-specific promoters are used.

Authors:  Colin P J Glover; Alison S Bienemann; Margaret Hopton; Thomas C Harding; James N Kew; James B Uney
Journal:  J Gene Med       Date:  2003-07       Impact factor: 4.565

Review 2.  Oncolytic adenoviruses as antiglioma agents.

Authors:  Hong Jiang; Frank McCormick; Frederick F Lang; Candelaria Gomez-Manzano; Juan Fueyo
Journal:  Expert Rev Anticancer Ther       Date:  2006-05       Impact factor: 4.512

3.  What is the blood-brain barrier (not)?

Authors:  Ingo Bechmann; Ian Galea; V Hugh Perry
Journal:  Trends Immunol       Date:  2006-11-30       Impact factor: 16.687

4.  Rapid upregulation of interferon-regulated and chemokine mRNAs upon injection of 108 international units, but not lower doses, of adenoviral vectors into the brain.

Authors:  Jeffrey M Zirger; Carlos Barcia; Chunyan Liu; Mariana Puntel; Ngan Mitchell; Iain Campbell; Maria Castro; Pedro R Lowenstein
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

Review 5.  Can the immune system be harnessed to repair the CNS?

Authors:  Phillip G Popovich; Erin E Longbrake
Journal:  Nat Rev Neurosci       Date:  2008-06       Impact factor: 34.870

6.  A model system for in vivo gene transfer into the central nervous system using an adenoviral vector.

Authors:  B L Davidson; E D Allen; K F Kozarsky; J M Wilson; B J Roessler
Journal:  Nat Genet       Date:  1993-03       Impact factor: 38.330

7.  High-capacity adenovirus vector-mediated anti-glioma gene therapy in the presence of systemic antiadenovirus immunity.

Authors:  Gwendalyn D King; A K M Ghulam Muhammad; Weidong Xiong; Kurt M Kroeger; Mariana Puntel; Daniel Larocque; Donna Palmer; Philip Ng; Pedro R Lowenstein; Maria G Castro
Journal:  J Virol       Date:  2008-02-20       Impact factor: 5.103

8.  Alterations in chemokine expression following Theiler's virus infection and restraint stress.

Authors:  W Mi; M Belyavskyi; R R Johnson; A N Sieve; R Storts; M W Meagher; C J R Welsh
Journal:  J Neuroimmunol       Date:  2004-06       Impact factor: 3.478

9.  Eight-year safety follow-up of coronary artery disease patients after local intracoronary VEGF gene transfer.

Authors:  M Hedman; K Muona; A Hedman; A Kivelä; M Syvänne; J Eränen; A Rantala; J Stjernvall; M S Nieminen; J Hartikainen; S Ylä-Herttuala
Journal:  Gene Ther       Date:  2009-02-12       Impact factor: 5.250

10.  Lipopolysaccharide intracerebral administration induces minimal inflammatory reaction in rat brain.

Authors:  C N Montero-Menei; L Sindji; A Pouplard-Barthelaix; F Jehan; L Denechaud; F Darcy
Journal:  Brain Res       Date:  1994-08-08       Impact factor: 3.252

View more
  17 in total

1.  Immune-mediated loss of transgene expression from virally transduced brain cells is irreversible, mediated by IFNγ, perforin, and TNFα, and due to the elimination of transduced cells.

Authors:  Jeffrey M Zirger; Mariana Puntel; Josee Bergeron; Mia Wibowo; Rameen Moridzadeh; Niyati Bondale; Carlos Barcia; Kurt M Kroeger; Chunyan Liu; Maria G Castro; Pedro R Lowenstein
Journal:  Mol Ther       Date:  2012-01-10       Impact factor: 11.454

2.  Increasing the effectiveness of intracerebral injections in adult and neonatal mice: a neurosurgical point of view.

Authors:  Bertrand Mathon; Mérie Nassar; Jean Simonnet; Caroline Le Duigou; Stéphane Clemenceau; Richard Miles; Desdemona Fricker
Journal:  Neurosci Bull       Date:  2015-09-07       Impact factor: 5.203

3.  Preclinical Efficacy and Safety Profile of Allometrically Scaled Doses of Doxycycline Used to Turn "On" Therapeutic Transgene Expression from High-Capacity Adenoviral Vectors in a Glioma Model.

Authors:  Nathan VanderVeen; Nicholas Raja; Elizabeth Yi; Henry Appelman; Philip Ng; Donna Palmer; Daniel Zamler; Marta Dzaman; Pedro R Lowenstein; Maria G Castro
Journal:  Hum Gene Ther Methods       Date:  2016-04-28       Impact factor: 2.396

4.  Combined Flt3L/TK gene therapy induces immunological surveillance which mediates an immune response against a surrogate brain tumor neoantigen.

Authors:  Gwendalyn D King; A K M Ghulam Muhammad; Daniel Larocque; Kyle R Kelson; Weidong Xiong; Chunyan Liu; Nicholas S R Sanderson; Kurt M Kroeger; Maria G Castro; Pedro R Lowenstein
Journal:  Mol Ther       Date:  2011-04-19       Impact factor: 11.454

5.  Lentiviral-induced high-grade gliomas in rats: the effects of PDGFB, HRAS-G12V, AKT, and IDH1-R132H.

Authors:  John Lynes; Mia Wibowo; Carl Koschmann; Gregory J Baker; Vandana Saxena; A K M G Muhammad; Niyati Bondale; Julia Klein; Hikmat Assi; Andrew P Lieberman; Maria G Castro; Pedro R Lowenstein
Journal:  Neurotherapeutics       Date:  2014-07       Impact factor: 7.620

Review 6.  Gene therapy for the nervous system: challenges and new strategies.

Authors:  Casey A Maguire; Servio H Ramirez; Steven F Merkel; Miguel Sena-Esteves; Xandra O Breakefield
Journal:  Neurotherapeutics       Date:  2014-10       Impact factor: 7.620

7.  Gene Therapy for the Treatment of Neurological Disorders: Central Nervous System Neoplasms.

Authors:  Neha Kamran; Marianela Candolfi; Gregory J Baker; Mariela Moreno Ayala; Marta Dzaman; Pedro R Lowenstein; Maria G Castro
Journal:  Methods Mol Biol       Date:  2016

8.  Natural killer cells eradicate galectin-1-deficient glioma in the absence of adaptive immunity.

Authors:  Gregory J Baker; Peter Chockley; Viveka Nand Yadav; Robert Doherty; Michael Ritt; Sivaraj Sivaramakrishnan; Maria G Castro; Pedro R Lowenstein
Journal:  Cancer Res       Date:  2014-07-18       Impact factor: 12.701

9.  Safety profile, efficacy, and biodistribution of a bicistronic high-capacity adenovirus vector encoding a combined immunostimulation and cytotoxic gene therapy as a prelude to a phase I clinical trial for glioblastoma.

Authors:  Mariana Puntel; Ghulam Muhammad A K M; Catherine Farrokhi; Nathan Vanderveen; Christopher Paran; Ashley Appelhans; Kurt M Kroeger; Alireza Salem; Liliana Lacayo; Robert N Pechnick; Kyle R Kelson; Sukhpreet Kaur; Sean Kennedy; Donna Palmer; Philip Ng; Chunyan Liu; Johnny Krasinkiewicz; Pedro R Lowenstein; Maria G Castro
Journal:  Toxicol Appl Pharmacol       Date:  2013-02-09       Impact factor: 4.219

10.  Intracerebroventricular viral injection of the neonatal mouse brain for persistent and widespread neuronal transduction.

Authors:  Ji-Yoen Kim; Stacy D Grunke; Yona Levites; Todd E Golde; Joanna L Jankowsky
Journal:  J Vis Exp       Date:  2014-09-15       Impact factor: 1.355

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.